GlassScriptPhysician profile
Sarah Farrokh
NPI 1588362677
$2,417.58
in general payments reported to CMS, 2019-2025
15 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $559 · 2024: $750 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965 · Education: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.66 |
| Education | $452.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $649.86 | 2024-2025 | |
| Janssen Biotech, INC. | $413.62 | 2024-2025 | Tremfya |
| Incyte Corporation | $258.86 | 2023-2025 | Opzelura |
| Abbvie INC. | $175.52 | 2023-2025 | |
| Galderma Laboratories, L.P. | $149.62 | 2024-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $131.60 | 2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $127.90 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $119.81 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $111.10 | 2023 | Arazlo |
| E.R. Squibb & Sons, L.L.C. | $99.99 | 2024 | Sotyktu |
| Orthofix Medical, INC. | $98.82 | 2023 | Physio-Stim |
| Genzyme Corporation | $26.45 | 2023 | |
| Genentech USA, INC. | $20.34 | 2024 | Xolair |
| Kyowa Kirin, INC. | $19.89 | 2025 | |
| Pfizer INC. | $14.20 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Farrokh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.